![]() ![]() ![]() If the phase I/II study generates positive data (expected in 2016), Kite Pharma intends to seek accelerated FDA approval for the treatment for patients with refractory DLBCL, PMBCL and TFL. The company’s lead pipeline candidate, KTE-C19, is currently in a multicenter phase I/II study in patients with refractory diffuse large B cell lymphoma (DLBCL) including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). With no approved products in its portfolio, investor focus will be primarily on the company’s cash burn and pipeline updates. Kite Pharma’s revenues comprise the amortization of deferred collaboration revenues related to the $60 million upfront payment received under its collaboration agreement with Amgen AMGN in the first quarter of 2015. These modified T-cells are designed to recognize and destroy cancer cells. The company uses its engineered autologous cell therapy (eACT) to genetically modify T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). Kite Pharma, a development-stage biopharmaceutical company, is looking to transform the paradigm of treating cancer which involves using the body’s immune system to recognize and destroy cancer cells. Let's see how things are shaping up for this announcement. In the last reported quarter, Kite Pharma posted a negative earnings surprise of 131.03%. Overall, the company posted an average negative earnings surprise of 289.58% over the past four quarters. The company, which started trading from Jun 2014, has posted negative earnings surprises in the last four trailing quarters. ![]() KITE is scheduled to report second-quarter 2015 results on Aug 10. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |